Pulse Oximeters Market Size Worth $3.2 Billion By 2027

The global pulse oximeters market size is expected to reach USD 3.2 billion by 2027, expanding at a CAGR of 6.4%, based on a new report by Grand View Research, Inc. Technological advancement in design and development of pulse oximeter is expected to boost market growth during the forecast period. Market players are introducing devices that are more compact, portable, ease to use, accurate, and efficient. For instance, in May 2019, Masimo received FDA clearance for its first tetherless SET pulse oximeter, Radius PPG.

Oxygen saturation monitors are conventionally used in pre and postsurgical settings. They are used during surgeries when patients are anesthetized. Increase in number of surgeries being performed and focus on patient safety are among the key factors responsible for increased use of the medical device during most procedures. These devices are purchased once and require servicing, without the need for frequent replacement. The use of oxygen saturation monitors in newborn screening can boost the demand and procurement of these devices by hospitals for maternity and pediatric care divisions.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/pulse-oximeter-market

Further key findings from the study suggest:

The sale of fingertip pulse oximeters has witnessed a significant spike since the first week of March 2020 due to COVID-19 pandemic
Handheld pulse oximeters are expected to be in high demand during the COVID-19 pandemic, as these devices are more accurate and come with probes that can be used for individual patients to limit spread of the virus
There is an upward trend in the use of oxygen saturation monitors in homecare settings due to expansion of the homecare market. Hospices and nursing care centers are procuring the medical device to provide better care to their patients
North America held the largest share in the market in 2019. Demand for oxygen saturation monitors is increasing in U.S. and Canada due to high prevalence of Congenital Heart Diseases (CHD) in infants
In Asia Pacific, the market is anticipated to witness significant growth during the forecast period. In countries such as Australia and New Zealand, oxygen saturation monitors are part of the standard patient observation procedures in hospitals and clinics. The device plays a vital role in monitoring and treatment of respiratory diseases in newborns and adults, as it provides independent information for a more comprehensive respiratory assessment
The industry is also witnessing mergers, acquisitions, and licensing agreements. For instance in April 2019, Philips Respironics moved the rights for direct sales of pulse oximeter in homecare market to Nonin Medical, an OEM manufacturer.

Healthcare Cloud Computing Market Size Worth $27.8 Billion By 2026

The global healthcare cloud computing market size is expected to reach USD 27.8 billion by 2026, according to a new report by Grand View Research, exhibiting a CAGR of 11.8% over the forecast period. The associated benefits of data analytics and increase in demand for flexible & scalable data storage by healthcare professionals is expected to drive the demand for these services over the forecast period.

Healthcare organizations are digitalizing their IT infrastructure and deploying cloud servers to improve features of systems. These solutions help organizations in reducing infrastructure cost & interoperability issues and aid in complying with regulatory standards. Hence, rising demand from health professionals to curb IT infrastructure costs and limit space usage are anticipated to boost market growth over the forecast period.

Increase in government initiatives undertaken to develop and deploy IT systems in this industry is one of the key drivers of this market. Moreover, increase in partnerships between private & public players and presence of a large number of players offering customized solutions are some of the factors anticipated to drive demand in the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/healthcare-cloud-computing-market

Further key findings from the report suggest:

Non-clinical information systems such as revenue cycle management, health information exchange, financial management, etc., accounted for the largest revenue share in application segment in 2018
Financial management segment held 23.0% share of the non-clinical segment in 2018 while billing and accounts management is expected to grow at the considerable CAGR during the forecast period
Private deployment model dominated the overall market owing to its benefits and ease of usage
Software as a Service (SaaS) model accounted for the largest revenue share as of 2018 as it is widely accepted. This model enables access to applications on a cloud from various devices
Pay-as-you-go pricing model is anticipated to gain popularity in the coming years, as the consumer only pays for services being used
North America dominated the market with a share of over 55.0% in 2018. This can be attributed to an increase in demand from payers as well as providers
Some key players of this healthcare cloud computing market include Athenahealth, Cerner Corporation, CareCloud Corporation, Carestream Corporation, Epic Systems Corporation, Dell Inc., and Sectra AB
Companies are forming various strategic alliances with clinical research organizations and medical devices companies to further expand their profit margins in the healthcare IT sector. These type of strategic collaborations are expected to aid market growth in the coming years.

Drug Eluting Stent Market Size To Reach $9.2 Billion By 2024

The global drug eluting stent market is anticipated to reach USD 9.2 billion by 2024, according to a new report by Grand View Research, Inc. The increasing geriatric population and the high prevalence of artery diseases are the major factors driving the market growth. Sedentary lifestyles, unhealthy dietary habits, and lack of exercise are some of the factors resulting in the increased prevalence of atherosclerosis. As a result, the demand for Drug Eluting Stents (DES) is escalating as atherosclerosis is widely treated using DES. In addition, a constant decline in the price coupled with the reimbursement coverage is spurring the adoption of DES in the treatment of arterial diseases.

Risks, such as thrombosis and disruption of regrowth of endothelial tissues associated with DES, are challenging the market growth. In addition, stringent regulatory approval guidelines are impeding the market growth by restricting the entry of advanced DES, such as bioabsorbable products, in the developed countries.

Presently, the DES market is highly fragmented with the presence of many players competing with each other. The key players in the market are implementing mergers and acquisitions strategies to strengthen their position in the market by the expansion of market share and customer base.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/drug-eluting-stent-market

Further key findings from the study suggest:

The polymer-based coating stent segment was dominating the global market and is estimated to remain dominant throughout the forecast period. The increasing adoption of biodegradable stents is mainly driving the growth of the polymer-based coating stents segment.
The biodegradable polymer-based drug eluting stents are anticipated to have a high demand during the forecast period due to a minimally invasive technique and lesser risk of late stent thrombosis.
The demand for polymer-free drug eluting stents is going to increase considerably with new products entering the market, especially in emerging countries such as Brazil, Mexico, and South Africa.
China, India, Brazil, and South Africa are anticipated to register a significant growth in the near future owing to the rising patient awareness related to DES, presence of the largest pool of geriatric population prone to arterial diseases, and the surging prevalence of chronic diseases such as diabetes and cardiac disorders
Less stringent regulatory approval procedures in Asia Pacific are offering the easy entry of the new products into the market.
Some key players operating in the market include Boston Scientific Corporation, Medtronic, Inc., Abbott Laboratories, Biosensors International Group, Lepu Medical Technology, Biotronik, Stentys, and Terumo Medical Corporation.

North America dominated the global market with a share of 40% in 2015. Technological advancements, such as the introduction of biodegradable stents primarily, led to the highest revenue generation in the region.
In addition, the reimbursement coverage, the presence of a large target patient population, and a well-defined regulatory framework are a few factors that are positively affecting the market.

Flexible Display Market Worth $39.19 Billion By 2025

The global flexible display market size is estimated to reach USD 39.19 billion by 2025, expanding at a CAGR of 28.1% over the forecast period, according to a study conducted by Grand View Research, Inc. Rising adoption of portable electronic devices is the major factor driving the growth. Flexible displays are lightweight, energy-efficient, and shatter-proof, which, in turn is driving their adoption for smartphone manufacturing.

Rising sales of consumer electronics, such as wearable devices, bendable TVs, and foldable laptops are expected to proliferate the demand for flexible displays during the forecast period. Furthermore, technological advancements in the manufacturing process of flexible Organic Light Emitting Diodes (OLED) has boosted the demand over the past few years.

Rising demand from industries, such as healthcare and automotive has opened new growth avenues for the flexible display market. Automotive manufacturers are focusing on integrating flexible displays in automotive interiors. For instance, in May 2019, Samsung Corporation and Audi AG formed a strategic partnership to push Audi’s concept car, Audi Prologue A9 Prototype. The proposed car is expected to house a flexible, high-resolution Samsung OLED display near the gear stick helping driver control vehicle settings.

Flexible display manufacturers are investing huge amounts in R&D in a bid to develop energy efficient products. In 2018, a total of 20,590 individual patents/applications were filed by the companies such as Sony Corp., Philips, Samsung Corporation and others. In October 2018, Royole Corporation, a flexible display and smart devices manufacturer, launched FlexPai, a foldable device which can be bent, rolled, and operated as a smartphone as well as tablet.

Thus, technological advancements in the field of displays are anticipated to provide sound growth opportunities to manufacturers and offer customers high-quality touch screen displays. However, huge capital investment requisite to manufacturing flexible substrate is expected to hamper the market growth during the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/flexible-display-market

Further key findings from the study suggest:

The OLED display segment is expected to register significant CAGR of more than 20.0% by 2025. The significant rise in adoption of OLED technology on account of its ability to reproduce full range picture without a stacked structure, keeping the picture quality intact, is expected to bode well for the segment growth
The plastic material segment accounted for over two-third of the total market share in terms of value in 2018 and is expected to expand at a CAGR exceeding 22.0% from 2019 to 2025. The dominance is majorly driven by the properties, such as durability and flexibility offered with respect to size and shape
The smartphone application segment is expected to expand at a noteworthy CAGR of 25% over the forecast period. Flexible displays are lightweight and shatter-proof, which is anticipated to drive the demand
Asia Pacific is expected to witness substantial growth in the forthcoming years, owing to the huge base of consumer electronics manufacturers along with the escalating demand for compact and light-weight electronic devices
The flexible display market is characterized by high competition with the presence of established players, such as BOE Technology Group Co., Ltd.; Corning Incorporated; Innolux Corp.; AU Optronics Corp.; E Ink Holdings, Inc.; Japan Display Inc.; LG Display Co., Ltd.; Royole; Samsung Electronics Co., Ltd.; and Sharp Corp. (Foxconn) among others
These players are making huge R&D investments in R&D to develop cost-effective material substrates for use in flexible displays. Companies are aggressively patenting technologies to get competitive advantage

Cardiac Resynchronization Therapy Market Worth $9.2 Billion By 2025

The global cardiac resynchronization therapy (CRT) market is expected to reach USD 9.2 billion by 2025, according to a new report by Grand View Research, Inc. The increasing prevalence of cardiac disorders and rising incidences of heart failure are expected to boost the CRT market growth over the forecast period.

According to statistics published by the Sudden Cardiac Arrest Foundation in 2016, about 6.0 million people within the U.S. region suffer from cardiac disorders, of which 0.8 million are affected by atrioventricular block leading to cardiac failure. Such a huge number leads to an increased cost of about USD 20.0-56.0 billion annually. CRT devices are being predominantly used to prevent the surgical cost and readmission rate in hospitals, thereby propelling its growth.

In addition, the on-going research to develop smaller, wireless/leadless and long-lasting CRT devices is expected to be a vital impact rendering driver. For instance, in September 2016, EBR Systems Inc. announced that it had attained the FDA Investigational Device Exemption (IDE) consent for its Wireless Stimulation Endocardially (WiSE) technology in the U.S.

This technology is capable of stimulating the left ventricle internally leading to superior performance in comparison to devices with pacing systems placed near the collar bone. The study is expected to be started by mid-2017 with complete support by the FDA in terms of regulatory compliance, and financial aid.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cardiac-resynchronization-therapy-devices-market

Further key findings from the study suggest:

CRT-D products are expected to dominate over the forecast period. According to a paper published in the Journal of Cardiovascular Electrophysiology, more than half of the CRT product implants are done using CRT-D.
Asia Pacific and Latin American regions are expected to witness lucrative growth and contribute over 30.0% of the revenue in 2025. This has been attributed to the rapid expansion of industry players within these regions in terms of manufacturing as well as distribution.
Competitive pricing and necessity for high operational optimization are expected to help companies strengthen their foothold in growing economies such as India, Mexico, and others.
Additionally, countries such as Japan are also observed to register a high adoption rate for quadripolar lead-based CRT-D devices. This is expected to further boost the market growth.
Major market players of the industry are Medtronic Plc., BIOTRONIK, LivaNova Plc., St. Jude Medical, and Boston Scientific. However, a more assorted marketplace exists for vendors of leads (wireless and wired) that are used in the system.

Life Sciences BPO Market Size To Reach $420 Billion By 2024

The life sciences BPO market is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.

The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.

In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth and profitability; altogether these trends are expected to boost the life sciences outsourcing market over the forecast period.

Favorable government initiatives such as the introduction of ICD-10 standards, the increasing adoption of Electronic Health Record systems (EHR), and digital health platforms are enabling the rapid growth of the back-end payer and provider BPO services, such as claims management, claims processing, financial and pay roll management, and other administrative services.

The rising geriatric population coupled with the growing prevalence of various chronic diseases is increasing the burden on the healthcare system and also driving the need for new drugs, and devices, which in turn is expected to boost the contract manufacturing and contract research services over the next nine years.

Moreover, the contract sales and marketing services segments are also expected to witness an increase in demand due to the growing sales and marketing activities for the new product launches over the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/life-science-bpo-market

Further key findings from the study suggest:

In 2015, the pharmaceutical outsourcing segment accounted for the largest revenue share, mainly on account of the growing demand for API and finished dosage form manufacturing services. Moreover, the increasing demand for early stage pre-clinical studies, clinical trials, post-marketing surveillance, and regulatory services are also expected to further drive the market over the forecast period.
The services segment including healthcare payer and provider BPO services is expected to emerge as the fastest growing services type with a CAGR of 9.3% over the forecast period
In the medical devices contract research outsourcing segment, the product design and development category accounted for nearly 29% in 2015. By 2024, the product implementation services are expected to emerge as the fastest growing category with a CAGR of 13.1% from 2016 to 2024.
North America was the largest regional market in 2015. The presence of several major pharmaceuticals, medical device, health insurance, contract research and contract manufacturing (CRAMS) players in this region are amongst the key factors responsible for the region’s large market share. The increasing geriatric population, the growing disease prevalence rates, the shift from ICD 9 to ICD 10 codes are significantly driving the healthcare expenditures and the need for efficient data management, as well as operational costs; therefore, these factors are expected to positively reinforce the life sciences outsourcing market over the forecast period.
Asia Pacific is expected to grow at a CAGR of11% over the forecast period. The increase in the number of U.S. FDA manufacturing sites in this region, especially China and India, the growing healthcare burden, patent expiration of several key drugs are expected to significantly boost the life sciences outsourcing market in this region.
Furthermore, favorable government initiatives to encourage the use of generic drugs, subsidies for the manufacturing of electronic components and devices, and several tax benefits to promote the export of life sciences services from this region are anticipated to further propel the market growth over the forecast period.
Some key market players include Infosys Limited, Lonza Group, PAREXEL International Corporation, Covance, Inc., International Business Machines Corporation. Genpact Limited, Catalent, Inc., ICON plc, Boehringer Ingelheim GmbH, Accenture plc, Quintiles Transnational Corporation, and Anthelio Healthcare Solutions

Rapid Urbanization Coupled With Need To Minimize Water Losses Is Expected To Drive The Global Smart Water Management Market

According to a new study by Grand View Research, Inc., water management has emerged as a significant priority for governments and water utilities, which is expected to fuel the global smart water management market. Infrastructure revitalization, growing population, fluctuating climate, and rise in water shortage issues are also some of the key forces driving the market growth. Although water management and conservation practices are continuously evolving, the aforementioned forces have spurred demand for smart technology solutions for more efficient and sustainable water systems.

Technological advancements enable water utility operators to proactively control and manage distribution systems and enhance efficiency, which is expected to favorably impact the market. The proliferation of cloud-based solutions to monitor distribution networks provides opportunities for market growth. Concerns among water utilities regarding the adoption of these solutions may pose a challenge to the market. Low adoption of smart water management systems by several water utilities owing to high investments is also expected to hinder the market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/smart-water-management-swm-market

Devices accounted for over 35% of the overall smart water management market, and emerged as the most dominant segment in 2013. Solutions are expected to be a high growth segment, which can be attributed to the development of cloud-based solutions for efficient monitoring of distribution networks.
Increasing adoption of cellular network technology in Automatic Meter Reading (AMR) is expected to drive market growth. The segment is also expected to grow faster than the global average over the next few years.
On account of favorable government initiatives including incubation facilities, financial incentives, and demonstration sites, North America was leading the regional market in 2013. Increasing investments in the U.S. water sector is expected to positively impact regional market growth over the forecast period.
Key market participants include Schneider Electric, Sensus, General Electric, IBM Corporation, and ABB Ltd. Strategic partnerships due to high investments and increasing competition are expected to be key growth strategies over the next six years.

In-Vitro Colorectal Cancer Screening Tests Market Is Expected To Reach USD 840.5 Million In 2022

The global market for In-Vitro Colorectal Cancer Screening Tests is expected to reach USD 840.5 million by 2022, according to a new study by Grand View Research, Inc. Increasing incidences of colorectal cancer and the development of novel CRC screening tests employing methods of genetic screening are some primary factors expected to drive market growth over the forecast period. The implementation of government regulations introducing compulsory application of cancer screening tests, introduction of minimally invasive tests which screen for CRC using DNA and genomic biomarkers, and the presence of high unmet needs are expected to fuel the growth of the in-vitro colorectal cancer screening tests market over the forecast period.

Apart from the already present genetic tests for CRC screening in the market, this segment of the market is relatively new and still in its nascent stages. Many biomarker tests are still under investigational research and yet others in their development phase. The major market players have significant products related to colorectal cancer screening using biomarkers and DNA screening in their development and approval pipelines which are expected to be fully commercialized within the next seven years. The introduction of these novel genetic tests in the market is expected to enhance revenue generation in the market and positively influence penetration rates.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/in-vitro-colorectal-cancer-screening-tests-market

Further key findings from the study suggest:

The in-vitro colorectal cancer screening tests market was found to be dominated by fecal occult blood tests owing to their higher usage rates and easy applicability to large groups of population at once for cancer screening. The more conventional guaiac FOB stool test, even though still occupy a significant share of the market, are expected to lose market share to their counterpart FOB tests which involve immunological testing along with the conventional testing.
The investigation and development of newer more accurate methods for colorectal cancer screening have led to the development of biomarker and DNA screening tests. Tumor M2-PK Stool test is currently the most widely used screening test among biomarker and DNA screening tests and is expected to gain revenue share over the forecast period.
North America accounted for the largest share of the in-vitro colorectal cancer screening tests market in 2014 owing to high incidences of colorectal cancer and presence of a large base of geriatric population in the region.
Europe accounted for a significant market share in 2014 owing to the presence of high cancer prevalence levels in the region. Colorectal cancer is the second most common cancer in both men and women after lung and breast cancer. Commission of the European Communities has estimated that 500 million screening examinations are expected to be conducted for colorectal and cervical cancer in the publicly mandated programmes in EU from 2010 to 2020.
Key participants of the in-vitro colorectal cancer screening tests market include Randox Laboratories, Sysmex, Immunostics, Beckman Coulter, Abbott Molecular, Epigenomics, Alere, Siemens Healthcare, Eiken Chemical, Kyowa Medex, Quest Diagnostics, Oncocyte, Companion Dx, Merck Millipore, ExiQon, Mode Diagnostics, and R-Biopharm.

Personalized Medicine Market Size Worth $3.18 Trillion By 2025

The global personalized medicine (PM) market size is expected to reach USD 3.18 trillion by 2025 registering a CAGR of 10.6% over the forecast period, according to a new report by Grand View Research, Inc. Growing number of approved companion diagnostics and biomarker products have been proved promising avenues for the development of advanced precision diagnostic tests. Several personalized diagnostics and therapeutic products based on companion diagnostics are under clinical trials and development pipelines, which also add an incremental opportunity to accelerate this market.

Gene therapies are widely utilized to diagnose both chronic and genetic disorders according to individual’s genetic makeup. Growing adoption of gene sequencing and data analytics technologies is anticipated to escalate precision medicine market growth. Decreasing cost of whole genome sequencing, advancement in cell biology sector, and the development of “Human Genome Project” are several other factors influencing the demand for gene therapy hence, boosting the overall market. Moreover, key leaders are undergoing numerous strategic developments to launch novel personalized products, which will also contribute to the market expansion.

For instance, in September 2018, Vertex Pharmaceuticals collaborated with Genomics for the delivery of precision medicine based on individual’s genetic differences and lifestyle. Similarly, in January 2018, Foundation Medicine collaborated with European Organization for Research and Treatment of Cancer (EORTC) to facilitate Foundation’s comprehensive genomic profiling to across personalized medicine and clinical trial enrolment.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/personalized-medicine-market

Further key findings from the study suggest:

PM therapeutics is projected to register the fastest CAGR over the forecast period owing to the development of high-capacity rapid sequencing platforms for medical therapies
Reduction in sequencing cost leads to an expected growth of genomic sequencing and genetic research, thus contributing to lucrative opportunities for genomic medicine
Asia Pacific is projected to be the fastest-growing regional market due to rising number of collaborative initiatives between eastern and western market leaders
Chinese personalized medicine market is benefitted due to initiatives implemented by the Chinese government and reimbursements for disease treatment
Prominent companies include GE Healthcare; Illumina, Inc.; Asuragen, Inc.; Abbott Laboratories; Dako A/S; Exact Science Corp.; and Biogen, Inc.

Pharmacy automation devices market to grow at 7.3% CAGR in 2020

Pharmacy automation involves automation and mechanization of tasks that include distribution and handling medication processes carried out in heath care centers and specialty pharmacy centers. The global pharmacy automation devices industry is projected to grow at a CAGR of 7.3% from 2014 to 2020 and reach over USD 8.99 billion.

Automation systems such as packaging and labeling systems, medication dispensing system, storage and retrieval systems, table-top counters and compounding systems are employed in order improve the efficacy of regular jobs within pharmacies. The market is expected to grow owing to features including system integration that increases productivity and time to clinicians for patient care, thereby lowering medication errors.

Rising demand for pharmaceutical products, progressively growing technology and demand for precise robotic equipment & tools to perform operations at a faster rate are expected to be the key factors for market growth. Untapped growth opportunities in countries such as Brazil, China, and India coupled with escalating demand for automation in pharmacy and healthcare operations is expected to drive growth over the forecast period.

The market was dominated by automated medication dispensing systems in 2013. It accounted for a share of over 47.8% owing to growing demand for accurate medication dispensing systems. Automated dispensing systems have the ability to reduce significantly error rates and the ability to dispense hands-free. They provide storage, recording of medication, distribution to resident care and computer controlled dispensation.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/pharmacy-automation-market

Automated compounding systems are anticipated to grow rapidly at a CAGR of 8.4% from 2014 to 2020 owing to an increasing demand for mixing of medication and substantial decrease in total time to complete a dose.

The existence of IT healthcare systems and high rate of penetration in healthcare and pharmaceutical units resulted in North America occupying the largest regional market in 2013. It accounted for about 54.8% of the market revenue. Increasing healthcare overheads and R&D relevant to pharmacy automation devices are few factors responsible for its market share.

Asia Pacific is likely to grow at a CAGR of over 9.0% during the forecast period and is the most lucrative regional markets majorly due to improving healthcare infrastructure in emerging economies of China and India. Easy access available to new entrants including multinational pharmaceutical companies and distributors in this region coupled with the introduction of healthcare reforms in these countries is expected to drive market growth.

Key industry players include AmerisourceBergen Corporation, CareFusion Corporation, Accu-Chart Healthcare, ForHealth Technologies, GSE Scale Systems, Fulcrum Inc,McKesson Corporation, Innovation PharmaAssist Robotics, Pearson Medical Technologies, Health Robotics SRL, Kirby Lester, MedDispence, Pyxis Pharmacy Automation Systems, Medacist, MTS Medication Technologies, OmnicellInc, Cerner Corporation, Rice Lake Weighing Systems, Baxter International Inc., Aesynt Inc., ScriptPro LLC, Parat Systems Pharmacy Automation, Yuyama Co. Ltd, Swisslog Holding Ltd,Talyst Inc. and ScriptPro LLC.